Abstracts tagged "autoantigens and biomarkers"

Abstract Number: 1737 • 2018 ACR/ARHP Annual Meeting
Multiplexed Autoantibody Profiles in a Systemic Sclerosis Clinical Trial Comparing Autologous Hematopoietic Stem Cell Transplantation and Cyclophosphamide
Paul J. Utz¹ and Burcu Ayoglu², ¹Medicine, Stanford University School of Medicine, Stanford, CA, ²Medicine, Stanford University, STANFORD, CA
Background/Purpose: In a randomized, open-label, phase II clinical trial (SCOT, Scleroderma: Cyclophosphamide or Transplantation)1, subjects were randomly assigned to treatment with myeloablative CD34+ selected autologous…
Abstract Number: 1079 • 2016 ACR/ARHP Annual Meeting
Discovery of Novel Autoantigens in Sjogren’s Syndrome with Potential for Subgrouping of Disease
Peter Schulz-Knappe¹, Petra Budde¹, Hans-Dieter Zucht¹, Heike Göhler¹, Klaus Marquart¹, Prof. Dr. Matthias Schneider² and Torsten Witte³, ¹Protagen AG, Dortmund, Germany, ²Department of Rheumatology, Univ. Duesseldorf, Duesseldorf, Germany, ³Department of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a common autoimmune disease with exocrine gland dysfunction and multi-organ involvement. With the growing interest in conducting clinical trials…
Abstract Number: 1862 • 2015 ACR/ARHP Annual Meeting
Identification of Homogeneous Systemic Lupus Erythematosus (SLE) Patient Groups Using Clustered Autoantibody Reactivities
Petra Budde¹, Hans-Dieter Zucht¹, Daniel Chamrad¹, Anna Telaar¹, Johannes Schulte-Pelkum¹, Stefan Vordenbäumen², Peter Schulz-Knappe¹ and Matthias Schneider³, ¹Protagen AG, Dortmund, Germany, ²Department of Rheumatology, Univ. Duesseldorf, Düsseldorf, Germany, ³Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany
Background/Purpose: In SLE, early diagnosis, differentiation to other autoimmune diseases and prognostic stratification are still great challenges. Hence, SLE represents an enormous challenge for the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].